Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.
about
Vaccines for preventing influenza in the elderlyFluad®-MF59®-Adjuvanted Influenza Vaccine in Older AdultsDevelopment of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic.Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challengeMF59™ as a vaccine adjuvant: a review of safety and immunogenicity.Inactivated influenza vaccines: recent progress and implications for the elderly.MF59 adjuvant: the best insurance against influenza strain diversity.Cost-effectiveness of adjuvanted versus nonadjuvanted influenza vaccine in adult hemodialysis patientsMF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile.Quantitative review of antibody response to inactivated seasonal influenza vaccines.Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adultsMF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.New adjuvants: EU regulatory developments.Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?Influenza and respiratory syncytial virus in the elderly.Towards identification of the mechanisms of action of parasite-derived peptide GK1 on the immunogenicity of an influenza vaccineCross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccinesInfluenza vaccines: unmet needs and recent developments.The virosomal adjuvanted influenza vaccine.MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk.Adjuvanted influenza vaccines.Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines.The appropriateness of the use of influenza vaccines: Recommendations from the latest seasons in Italy.Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries.
P2860
Q24239997-59BBCC43-F4B0-4BA6-8D82-87AA30399E88Q27009478-7ADC4DE9-E68C-458A-9908-5D5F7D6589B7Q30360869-F1BB3F8E-2351-4E2A-AB9D-E5E712BAA864Q30376482-CA7CDC1E-B387-44A0-9739-4F3893F7B288Q30394545-1BEFDC01-372B-461D-84D8-932199B1DF26Q30399057-F6C4A26D-850F-4ED4-B1D2-4E837286ED24Q30402018-8BA43406-EF6C-4E63-83B0-6FB9996381BBQ34903425-FAC8B769-D816-4927-A470-CB4A6E4872F5Q35192178-09CE59B6-B917-4D9B-AF07-0B08123176A6Q35218808-487153F5-42C6-4213-A2E3-49B22D46BBCFQ35887679-F6AEE119-C13E-483B-83A8-952E08353B35Q36363243-01E8D52B-5982-47A5-99B1-BBFBEBD26529Q36452409-8BCDDC12-1A36-4C6E-A20D-BEA3A7B84228Q36968246-65C608E1-8143-4F4C-B077-7C5874836AAEQ36968305-B8EDA28C-9F66-47F1-8186-BE3ED38873DBQ37084793-E1DA7F78-B4E1-4E5C-A12D-9421A7616E67Q37103929-82E872C8-0361-4DC3-A7AF-239918E1002FQ37349250-47A16B9A-A31A-4DA6-98D8-F435CE6990C8Q37478319-255348EC-91FC-42C3-84A9-63362B859B2EQ37518273-D846E1B7-E65A-4107-AF1B-E68616A7C148Q37678409-CE13B873-663C-4276-A53B-40664F7F2D42Q37706610-A8EDCAE6-A7B6-493D-928B-3FCE3D5684C1Q37976540-0D875E68-239F-41CE-A2D0-774245DB7BE0Q40471889-47016791-4C35-4644-8D2B-FC5B64625AB2Q48145472-E1F15569-7CC4-4FDC-95F7-07EE5CDE5B1DQ51119752-ED681896-8F44-4AA3-A314-38A1D421EAFDQ54626497-73179143-7881-48E7-85B8-981E89914D38
P2860
Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Comparison of the reactogenici ...... a vaccine in elderly subjects.
@en
type
label
Comparison of the reactogenici ...... a vaccine in elderly subjects.
@en
prefLabel
Comparison of the reactogenici ...... a vaccine in elderly subjects.
@en
P2093
P1433
P1476
Comparison of the reactogenici ...... za vaccine in elderly subjects
@en
P2093
E Perinetti
S Squarcione
P304
P356
10.1016/S0264-410X(02)00401-2
P407
P577
2003-03-01T00:00:00Z